Cambium Bio Limited has released a press release.
FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
Earlier from Cambium Bio
- Half Year Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Cambium Bio Secures A$2.4 Million Strategic Investment
- Cambium Bio Signs Strategic MoU with Benta SAS